Text Size

Cortisol in the Treatment of Phobias

This study has been completed.
Sponsor:
Collaborator:
University Hospital, Basel, Switzerland
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00451750
First received: March 21, 2007
Last updated: January 11, 2010
Last verified: January 2010
History of Changes
  Purpose

The aim of this prospective, double-blind, placebo-controlled, randomized study is to investigate if glucocorticoid treatment, in combination with exposure therapy, helps to reduce phobic fear in patients with phobia.


Condition Intervention
Phobia
 Drug: Cortisol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias

Resource links provided by NLM:

MedlinePlus related topics: Phobias
U.S. FDA Resources

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • visual analog scales for fear and acrophobia questionnaires [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: May 2007
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cortisol
    20 mg for 3 times
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Female and male patients with a specific phobia (fear of heights) according to DSM-IV criteria.

Exclusion Criteria:

  • Severe acute or chronic somatic diseases
  • Psychiatric disorder other than specific phobia
  • Topic glucocorticoid therapy (for large skin parts)
  • Inhaled glucocorticoids
  • Psychotropic medication
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00451750

Locations
Switzerland
University of Basel
Basel, Switzerland, 4055
Sponsors and Collaborators
University of Zurich
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Dominique JF de Quervain, MD, Prof. University of Zürich
Principal Investigator: Frank Wilhelm, Prof. University of Basel
  More Information

Publications:

Responsible Party: Dominique de Quervain, Prof. MD, University of Zurich
ClinicalTrials.gov Identifier: NCT00451750     History of Changes
Other Study ID Numbers: 2007DR3069
Study First Received: March 21, 2007
Last Updated: January 11, 2010
Health Authority: Switzerland: Swissmedic
Switzerland: Ethical committee, Zürich Switzerland

Keywords provided by University of Zurich:
phobia
cortisol
memory
treatment

Additional relevant MeSH terms:
Phobic Disorders
Anxiety Disorders
Mental Disorders
Cortisol succinate
Hydrocortisone acetate
Hydrocortisone 17-butyrate 21-propionate
 Hydrocortisone
Hydrocortisone-17-butyrate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Dermatologic Agents

ClinicalTrials.gov processed this record on May 21, 2013